{
  "consolidation_metadata": {
    "timestamp": "2025-09-10T11:25:22.442234",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "picos",
    "total_consolidated_picos": 28,
    "source_countries": [
      "AT",
      "DE",
      "DK",
      "EN",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_picos": [
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "PT",
        "PO",
        "SE",
        "EN",
        "DK",
        "AT",
        "NL"
      ],
      "Source_Types": [
        "hta_submission",
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "adult patients with advanced non-small cell lung cancer (NSCLC) with a KRas g12c mutation who have experienced disease progression after at least one line of previous use",
        "adult patients with advanced NSCLC with a KRAS G12C mutation, following progression from at least one prior line of systemic therapy",
        "patients with advanced NSCLC with a KRAS-G12C mutation that has progressed after at least one systemic therapy",
        "patients with non–small-cell lung cancer stage IIIB/IV and an KRAS G12C mutation",
        "previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer"
      ],
      "Original_Comparator_Variants": [
        "docetaxel",
        "docetaxel monotherapy"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel + nintedanib",
      "Countries": [
        "PT",
        "PO",
        "DE",
        "EN"
      ],
      "Source_Types": [
        "hta_submission",
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "sotorasib (SOT) was compared with docetaxel (DOC), nintedanib in combination with docetexel (NIN+DOC) and pemetrexed (XPM)",
        "previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer"
      ],
      "Original_Comparator_Variants": [
        "docetaxel + nintedanib",
        "docetaxel in combination with nintedanib",
        "nintedanib in combination with docetaxel",
        "docetaxel plus nintedanib"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pemetrexed",
      "Countries": [
        "PT",
        "PO",
        "DE",
        "NL"
      ],
      "Source_Types": [
        "hta_submission",
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "sotorasib (SOT) was compared with docetaxel (DOC), nintedanib in combination with docetexel (NIN+DOC) and pemetrexed (XPM)",
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "pemetrexed"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "nivolumab",
      "Countries": [
        "PT",
        "PO",
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "nivolumab"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pembrolizumab",
      "Countries": [
        "PT",
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "pembrolizumab"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab",
      "Countries": [
        "PT",
        "PO",
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "atezolizumab"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "platinum doublet",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy"
      ],
      "Original_Comparator_Variants": [
        "platinum doublet"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "chemotherapy",
      "Countries": [
        "FR",
        "NL",
        "IT"
      ],
      "Source_Types": [
        "hta_submission",
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced CBNPC, with KRAS G12C mutation, whose disease has progressed after at least one prior systemic treatment line",
        "patients with non–small-cell lung cancer stage IIIB/IV and a KRAS G12C mutation",
        "metastatic, p. G12C mutant KRAS NSCLL patients progressing following prior platinum-based chemotherapies"
      ],
      "Original_Comparator_Variants": [
        "chemotherapy"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "immunotherapy",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced CBNPC, with KRAS G12C mutation, whose disease has progressed after at least one prior systemic treatment line"
      ],
      "Original_Comparator_Variants": [
        "immunotherapy"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "gemcitabine",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "metastatic NSCLC harboring a KRAS mutation, who received prior chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "gemcitabine"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "erlotinib-tivantinib",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "metastatic NSCLC harboring a KRAS mutation, who received prior chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "erlotinib-tivantinib"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sotorasib",
      "Countries": [
        "DE",
        "DK"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "Patients with Stage IV NSCLC with a KRAS-G12C mutation who have experienced failure of at least one systemic therapy",
        "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy"
      ],
      "Original_Comparator_Variants": [
        "Sotorasib",
        "sotorasib"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "adagrasib",
      "Countries": [
        "DK",
        "FR",
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline",
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients with active KRAS G12C and 0-2 performance status and previously treated with platinum-based chemotherapy and immunotherapy (where applicable)",
        "adult patients with advanced non-small cell adagrasib bronchial cancer (ASBC) with KRAS G12C mutation, whose disease has progressed after at least one prior systemic therapy",
        "the second-line treatment of patients with NDRP with a KRAS G12C mutation"
      ],
      "Original_Comparator_Variants": [
        "adagrasib"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "chemotherapy (docetaxel or pemetrexed)",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "the second-line treatment of patients with NDRP with a KRAS G12C mutation"
      ],
      "Original_Comparator_Variants": [
        "chemotherapy (docetaxel or pemetrexed)"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "EGFR inhibitors (in patients who have not received these medicines in the first line)",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "the second-line treatment of patients with NDRP with a KRAS G12C mutation"
      ],
      "Original_Comparator_Variants": [
        "EGFR inhibitors in patients who have not received these medicines in the first line"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "osimertinib (in patients previously treated with first or second generation EGFR blockers)",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "the second-line treatment of patients with NDRP with a KRAS G12C mutation"
      ],
      "Original_Comparator_Variants": [
        "osymertinib in patients previously treated with first or second generation EGFR blockers"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "ALK inhibitors (if ALK gene rearrangement)",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "the second-line treatment of patients with NDRP with a KRAS G12C mutation"
      ],
      "Original_Comparator_Variants": [
        "ALK inhibitors if ALK gene rearrangement"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel in combination with ramucirumab",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy and for whom a therapy other than docetaxel is the appropriate patient-individual therapy"
      ],
      "Original_Comparator_Variants": [
        "docetaxel in combination with ramucirumab"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "afatinib",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy and for whom a therapy other than docetaxel is the appropriate patient-individual therapy"
      ],
      "Original_Comparator_Variants": [
        "afatinib"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "erlotinib",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy and for whom a therapy other than docetaxel is the appropriate patient-individual therapy"
      ],
      "Original_Comparator_Variants": [
        "erlotinib"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "vinorelbine",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy and for whom a therapy other than docetaxel is the appropriate patient-individual therapy"
      ],
      "Original_Comparator_Variants": [
        "vinorelbine"
      ]
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and tumours expressing PD-L1 with a TPS ≥1%",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pembrolizumab",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "tumours expressing PD-L1 with a TPS >=1%"
      ],
      "Original_Comparator_Variants": [
        "pembrolizumab"
      ]
    },
    {
      "Population": "Patients treated with immunotherapy monotherapy in the first line (advanced NSCLC with KRAS G12C mutation)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "platinum-based chemotherapy regimens (cisplatin-vinorelbine, cisplatin-gemcitabine, carboplatin-paclitaxel, cisplatin-docetaxel, cisplatin-pemetrexed [non-epidermoid only])",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Patients treated with immunotherapy monotherapy in the first line"
      ],
      "Original_Comparator_Variants": [
        "chemotherapy based on platinum salts, such as in the 1st line: cisplatin-vinorelbine, cisplatine-citagembine, carboplatin-paclitaxel, cisplain-docetaxel, Cisplatin-pemetrexed (non-epidermoid only)"
      ]
    },
    {
      "Population": "Patients treated with chemotherapeutic therapy + immunotherapies in the first line (advanced NSCLC with KRAS G12C mutation)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pemetrexed, docetaxel (non-epidermoid only)",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients treated with chemotherapeutic therapy + immunotherapies in the line 1"
      ],
      "Original_Comparator_Variants": [
        "chemotherapists in the single line: pemetrexed, docetaxel (non-epidermoside only)"
      ]
    },
    {
      "Population": "Patients receiving first line bi-chemotherapy, without immunotherapy (advanced NSCLC with KRAS G12C mutation)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab, nivolumab, pembrolizumab (if PD-L1 ≥ 1%)",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients receiving first line bi-chemotherapy, without immunotherapy"
      ],
      "Original_Comparator_Variants": [
        "immunotherapeutic treatment: atezolizumab, nivolumab or pembrolizimab (if PD-L1 ≥ 1%)"
      ]
    },
    {
      "Population": "Patients receiving first line bi-chemotherapy, without immunotherapy (advanced NSCLC with KRAS G12C mutation)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel, pemetrexed (non-epidermoid only)",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients receiving first line bi-chemotherapy, without immunotherapy"
      ],
      "Original_Comparator_Variants": [
        "docetaxel, pemetrexed (non-epidermoid only)"
      ]
    },
    {
      "Population": "Patients receiving first line bi-chemotherapy, without immunotherapy (advanced NSCLC with KRAS G12C mutation)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "paclitaxel + bevacizumab",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients receiving first line bi-chemotherapy, without immunotherapy"
      ],
      "Original_Comparator_Variants": [
        "paclitaxel + bevacizumab"
      ]
    }
  ]
}